Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
Teva's Battered Stock Looks Extremely Cheap | Barron's
Teva Appoints New Chief Executive After Months of Speculation - WSJ
Teva's latest quarter was even worse than already-low expectations - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Investors wary of Teva-Mylan merger - MarketWatch
Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals - Wikiwand
Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Teva Pharmaceutical's Stock Tumbles on Outlook - WSJ
Teva's CEO Kåre Schultz to retire at year end, succeeded by Richard Francis
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Stock Pressured From Antitrust Lawsuit Against Drug Makers | Barron's
Warren Buffett Stocks Fall: Teva Pharmaceutical Up 1.8%; StoneCo Off 3.7% - TheStreet
Teva Pharmaceuticals - Wikiwand
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Coming Back
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
Teva Pharmaceutical Is Bottoming: Here's My Strategy - RealMoney
Teva - Updates, News, Events, Signals & Triggers
Teva Pharmaceuticals - Wikipedia
Teva earnings preview: Opioid suits are 'key' - MarketWatch
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
